In order to explore the expression and clinical significance of egl-9 family hypoxia-inducible factor 1 (EGLN1) in clear cell renal cell carcinoma (ccRCC), based on the gene expression data of ccRCC patients in the TCGA database to analyze EGLN1 in ccRCC tissues and normal kidney tissues, the difference in expression of EGLN1 in ccRCC was analyzed using the UALCAN platform. Based on the ccRCC clinical data in the TCGA database, the survival analysis of the EGLN1 high and low expression group, the Cox analysis of the correlation between EGLN1 expression and overall survival, and the gene enrichment analysis of the EGLN1 gene expression in the clinical data were performed. The possible potential interactions between encoded proteins were searched through the STRING database, and a protein interaction network was constructed to express them, obtain EGLN1 related proteins, and perform related analysis on the GEPIA platform. Analysis of the sample expression data in the TCGA database shows that the expression of EGLN1 in ccRCC is higher than that in normal kidney tissue. The analysis of the UALCAN platform found that the high expression of EGLN1 is correlated with the age of the patient. Survival analysis showed that ccRCC patients had a better prognosis when EGLN1 was overexpressed. Univariate and multivariate Cox analysis indicated that the expression of EGLN1 is an independent risk factor for the survival of ccRCC patients. Gene enrichment analysis suggests that the expression of EGLN1 gene is closely related to RCC pathway, ubiquitin-mediated proteolysis pathway, and apoptosis pathway. The results show that EGLN1 may be a molecular marker for evaluating the prognosis of ccRCC.